^
Association details:
| Biomarker: | RB1 deletion |
|---|---|
| Cancer: | Mesothelioma |
| Drug: | volasertib (NBL-001) (PLK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Integrated genomics point to immune vulnerabilities in pleural mesothelioma
Published date:
09/27/2021
Excerpt:
We also found previously unrecognised deletions in RB1 in 26% of cases and show sub-micromolar responses to downstream PLK1, CHEK1 and Aurora Kinase inhibitors in primary mesothelioma cells.
DOI:
https://www.nature.com/articles/s41598-021-98414-w
